ESR1 and inflammatory breast carcinoma: Estrogen receptor (ER) and progesterone receptor (PR) expression by immunohistochemical (IHC) analysis is commonly used as a predictive marker for endocrine treatment as well as a prognostic indicator in non-IBC [3, 4].